IFF Secures Regulatory Approval for Use of 2'-FL HMO in China

Argus Session date unavailable

+3.22% session move Open Argus

Details

News Market Reaction – IFF

The recorded move for IFF in the trading session of this news was +3.22%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Landmark decision marks first-time approval of human milk oligosaccharide molecules for infant formula in China 

SHANGHAI, Oct. 9, 2023 /PRNewswire/ -- IFF, a global leader in food, beverage, health, biosciences and scent, today announced it is one of the first ingredients suppliers to achieve regulatory approval (NHC No. 8, 2023) for the use of its 2′-fucosyllactose (2'-FL), human milk oligosaccharide (HMO) in China for infant formula, follow-up formula and formula for special medical purposes for infants. The news is a significant milestone that signifies IFF's position as a key supplier of this vital constituent of human milk to the Chinese market.

HMOs—including 2'-FL, 3'-FL and others—have been gradually appearing in the U.S. and European markets for several years now. Their introduction to infant formula is propelled by numerous studies conducted on human milk, as well as formula containing 2'-FL, which suggested such products showed pronounced immune health benefits in infants.

China has the largest milk formula segment worldwide, representing close to 50 percent of the global market's total retail value.^[1] Until today, HMO molecules were not approved for use in infant formula in China. The announcement of the landmark decision means brand owners and infant formula producers can now look to further support families across the Asia-Pacific region, and beyond.

"The infant formula industry has eagerly awaited the approval of 2'-FL in China, since it will allow producers to formulate a new generation of products for the early-life nutrition segment," said Marcus Gliwitzki, global product manager, Health, IFF. "Today's decision will help us better serve customers in all major markets and respond to the rising global demand for infant nutrition products."

"We are thrilled to contribute to bringing infant formula closer to human milk," said Klaas Illeghems, global strategic business unit leader, INFAT^®, HMO & Biosciences, Health, IFF. "This is our first HMO ingredient for the Chinese market, and we are committed to accelerate more of our high-quality HMOs to customers soon."

This regulatory milestone marks the intersection of IFF's extensive HMO research and innovation, commercialization, and health benefit effects – via infant gut microbiome modulation – closing an important gap between human milk and infant formula.

¹ Euromonitor: Dairy Products and Alternatives: Euromonitor from trade sources/national statistics.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, X (Twitter) , Facebook, Instagram, and LinkedIn. 

©2023 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ^SM or ^®are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

 

SOURCE IFF